Unassociated Document


 



Exhibit 10.16


 


ADMA Biologics, Inc.


Confidential Materials Omitted and Filed Separately with the


Securities and Exchange Commission


Confidential Portions denoted by [***]


 


Testing Services Agreement


 


THIS TESTING SERVICES AGREEMENT (“the Agreement”) is made effective as of the date last signed below (the “Effective Date”) by and between [***]), with a principal office located at [***] and ADMA Biologics, Inc. with a principal office located at 65 Commerce Way, Hackensack, NJ 07601 (“Client”) for [***] (the “Project”).  [***] and Client shall each herein be referred to as a “Party” and together as the “Parties.”







Background







[***] provides laboratory testing and related services (“[***]”) to pharmaceutical, bio-technology, and other companies involved in pharmaceutical and medical research and product development.  Client wishes to engage [***] to perform Services, including services which are exclusive to Client, as described in Exhibit A (collectively, the “Services”), and both parties wish to set forth their respective rights, duties, and obligations in connection therewith.







1.           SERVICES







1.1           Provision of Services.  [***] shall provide Services in accordance with this Agreement, inclusive of the [***] attached hereto as Exhibit A and the Estimated [***] Budget attached hereto as Exhibit B, and all applicable laws and regulations.







1.1.1           Project Manager.  [***] will assign a Project Manager to interact on a regular basis with Client, coordinating and monitoring the Services provided by [***] for the Project.  Client is responsible for ensuring that all updated versions of the Project [***] or any Project [***] amendments are sent to the [***] Project Manager.







1.2           Affiliates.  “Affiliate” shall mean any entity that directly or indirectly controls, is controlled by or is under common control with a Party through the ownership of a majority of the outstanding voting securities or by contract.  For purposes of this provision, the term “control” shall mean the power to either direct or cause the direction of the management of the entity or, in [***] case, the management of the Services performed under this Agreement.  Notwithstanding anything in this Agreement to the contrary, [***] shall have the right to provide Services hereunder through its Affiliates without prior approval of Client.  [***] agrees to notify Client in writing [***] of its decision to provide any services to Client through an Affiliate.  [***] shall remain fully responsible to Client for the performance of such Services.







1.3           Storage Limitations.  If requested by Client and agreed by [***], [***] will [***] at the conditions [***] agreed to between the parties for the time period defined by Client in the Project [***].  [***] cannot guarantee that [***] will remain stable and suitable for testing or that stability data will be available during or after that storage time period.  [***] guarantees that any and all [***] will be maintained under industry standard [***].  Client should review the [***] with [***] Scientific Affairs department prior to [***].  If the [***] is unknown, the Client must define the [***], [***] duration, and testing interval of the [***].  Should [***] determine that any [***] were not [***] as set forth in the Project [***], [***] shall provide prompt notification of such to Client and shall promptly undertake all remediation actions as reasonably requested by Client.


 


[***]


 




  





Page 1 of 19











  






 


1.4           Cancellation/Revision/Delay







1.4.1           Cancellation.  If a Project is cancelled by Client after [***] has been authorized to initiate start-up Services, Client agrees to reimburse [***] for (i) the project management, data management and logistics set-up fees specified in the Budget, (ii) any applicable fees for Services rendered in accordance with the Budget, including any collection kits that have been prepared or distributed, and (iii) the purchase of any specialized testing reagents and/or supplies.







1.4.2           Revision.  If the Project is revised after Project materials have been approved, including but not limited to (i) requisition forms, (ii) investigator manuals, and (iii)  [***]/transport supplies, Client agrees to pay [***] for Services rendered and costs incurred in the revision or replacement of previously-approved Project materials and supplies, and any costs associated with database changes resulting from Project revision.







1.4.3           Delay.  If Client delays the initiation or conduct of a Project protocol to the extent that [***]/transport supplies and/or specialized testing reagents expire, Client agrees to pay [***] for costs incurred to replace expired supplies and/or specialized testing reagents.







2.           COMPENSATION







2.1           Billing and Payment Terms.  [***] will bill Client for Services once per month.  Charges will be billed at the rates agreed to in Exhibit B, subject to any adjustments permitted in this Agreement.  It is a material term of this Agreement that Client shall pay all undisputed amounts [***] of the date of an invoice for Services.  In addition to any other remedies provided for under this Agreement, [***] reserves the right to charge a late fee of up to [***] on any undisputed amounts outstanding for [***] from Client's receipt of an invoice for Services.







2.2.           Upon written notice to Client of non-payment hereunder and failure of Client to cure such non-payment [***] from receipt of such notice, [***], at its sole option, may suspend further performance of its duties and obligations hereunder until all outstanding undisputed amounts are fully paid.  Any suspension by [***] shall extend any deadlines for performance by [***] of its duties and obligations under this Agreement for a time period equal to the number of days between the date of receipt of [***] notice of suspension and the date [***] receives full payment of all outstanding undisputed amounts.


 


Invoices shall be sent to:


Company Name:  ADMA Biologics, Inc.


Address: 65 Commerce Way, Hackensack, NJ 07601


Attention:  Accounts Payable


Phone Number of remittance person: (201) 478-5552







                              and







Electronic invoices shall be sent to:


E-mail address:  [***]


Attention: [***]


Phone number:  (201) 478-5552


 


[***]


 




  





Page 2 of 19











  






 


2.3.          Payments:








2.3.1           US payments shall be made by check payable to [***], Tax ID Number [***]










	
If payment by check:

	
If payment is by Bank Transfer/Wire Transfer:


	
[***]


[***]


[***]


[***]


 


 

	
Send to: [***]


ABA Routing Number: [***]


Account Number: [***]


Swift Number [***]


Telex Number: [***]


*Please identify the invoice numbers being paid.












2.3.2           Final Invoice.  [***] shall complete its invoicing process [***] after communication of Project completion.  If any [***] remain in storage, or if other Services are still to be performed, the parties agree that invoicing shall continue until such [***] are removed from [***] storage facilities, or relevant Services are completed.







2.3.3           Fee Increases.  [***] may offset any increased costs of operations by [***] written notice to Client.  Any such increase shall not exceed the [***] ending on the last day of the month immediately preceding the effective date of the increase, as measured (i)   in the United States, by the [***].







2.4            Taxes.  Client shall pay any sales, use, excise, transfer, value-added, goods and services, services, consumption, or other similar tax (if any) imposed by any governmental authority in connection with, or attributable to, Client's receipt of the Services hereunder or in connection with, or attributable to, the issuance of any invoice by [***] to Client for such  Services.  [***] shall be entitled to invoice Client for any such taxes as may be required by applicable law, and Client shall pay such amounts as invoiced by [***].








	
3.

	
TERM AND TERMINATION












3.1           Term.  This Agreement shall be effective as of the Effective Date, and shall terminate at the conclusion of the Project Services, unless earlier terminated as provided herein.







3.2           Termination.







3.2.1.           For Material Breach.  If either party (the “non-breaching party”) believes the other party (the “breaching party”) is in material breach of any obligations hereunder, the non-breaching party shall have the right to terminate this Agreement by providing the breaching party with written notice specifying the material breach(es) and indicating clearly its intention to terminate the Agreement [***] after the breaching party receives such notice.  If the breaching party cures such breach within such [***], the non-breaching party’s notice shall be void.  If the breaching party does not cure such breach within such [***], the Agreement shall terminate at the end of such [***].







3.2.2.           Without Cause.  Either party may terminate this Agreement by providing the other party with written notice of termination at least [***] prior to the effective date of such termination.


 


[***]


 




  





Page 3 of 19











  






 


3.2.3           Effect of Termination.  Unless otherwise provided specifically in (a) this Agreement or (b) a separate written document signed by both parties, upon termination or expiration of this Agreement, the parties shall each be released from their obligations hereunder, and this Agreement shall have no further force or effect; provided, however, that Sections 2, 3.2.3, 4, 5, 6, 7, 8.1, 11.2, 11.3, 11.5, 11.6, 11.8 and 11.9 shall survive termination of this Agreement.




 


4.           INTELLECTUAL PROPERTY







4.1           Client Ownership of Data; Inventions. All data, test results, studies and other information generated by [***] in performing the Services (the “Data”) shall be the property of the Client.  All proprietary, non-public information concerning (a) the Project, (b) materials, compounds, formulations, methods, processes, Assays and drugs or proprietary reagents used in or for the Project, and (c) Client’s operations (including basic scientific data, prior clinical or laboratory data, formulation information, and research programs supplied by Client to [***] and not in the public domain) (“Client’s Confidential Information”) shall be considered confidential and shall remain the sole property of Client.  Further, except as otherwise provided in Section 4.2 below, all rights to any discovery or invention conceived (or conceived and reduced to practice) in the direct performance of the work conducted under this Agreement (each, an “Invention”) shall belong to Client.  [***] shall promptly disclose to Client any Invention arising from this Agreement.  [***] agrees to assign to Client, upon written request of Client, the sole and exclusive ownership of any Invention hereunder, subject to payment by Client of all reasonable expenses incurred by [***] in connection therewith.  Any further protection or perfection of such Invention shall be Client’s responsibility.  [***] represents, warrants and covenants that all persons involved in or working on the Project on behalf of [***] and/or its Affiliates have assigned or shall assign all right, title and interest in and to all Data and Inventions to Client.


 


4.2           [***] Intellectual Property. Notwithstanding anything in this Agreement to the contrary, Client and [***] agree that [***] possesses certain intellectual property, including but not limited to inventions, know-how, trade secrets, analytical methods, standard operating procedures, computer technical expertise, software and statistical methodologies originated by [***] prior to or under or during the term of this Agreement without benefit of Information provided by Client that is the sole property of [***] (“[***] Intellectual Property”).  Further, to the extent that [***] makes any improvement or addition to [***] Intellectual Property relating solely to central or diagnostic laboratory analyses and services and/or medical diagnostic assays and methods in the course of performing this Agreement or otherwise, such improvement and/or addition to [***] Intellectual Property shall be the sole and exclusive property of [***].  Finally, in the course of working with [***] hereunder, Client may become aware of other, non-public information about [***] and its business that [***] considers confidential, which shall be considered confidential and shall remain the sole property of [***] (such information, together with [***] Intellectual Property, is referred to hereinafter as “[***] Confidential Information”).


 


4.3           Limitations on Use of Assay.  [***] agrees and acknowledges that Client paid for the development and validation of the testing assay (“Assay”) and as such, the testing assay is the sole property of the Client and shall only be utilized for the Client.


 








	
5.

	
CONFIDENTIALITY OBLIGATIONS












5.1           Protection and Non-use of Confidential Information. [***] and Client each agree to keep in strict confidence and not to disclose Confidential Information of either Party hereto or their Affiliates or subsidiaries to any third party or use such Confidential Information for any purpose other than for the performance of this Agreement without the prior written consent of the other Party hereto.  Each Party may disclose the other Party’s Confidential Information to its Affiliates, employees and agents performing any of that Party’s obligations or Services hereunder who have a need to know such Confidential Information and are bound by obligations of confidentiality and non-use equal to or greater than those contained herein.  Each Party agrees to maintain the other Party’s Confidential Information with a reasonable level of protection from disclosure (but in no event less than that accorded its own Confidential Information), and to take all reasonable precautions to prevent the unauthorized disclosure to any third party of the Confidential Information that it receives hereunder.  The above notwithstanding, the receiving Party’s obligations of confidence and non-use with respect to the Confidential Information disclosed hereunder shall not include:


 


[***]


 




  





Page 4 of 19











  








 


(a) Information that at the time of disclosure to the receiving Party is in the public domain, or that thereafter becomes part of the public domain through no fault of the receiving Party;


 


(b) Information that is known to the receiving Party prior to the time of disclosure to the receiving Party, as evidenced by its contemporaneous written records;


 


(c) Information that has been or is disclosed to the receiving Party in good faith by a third party who was not, or is not, under any obligation to keep the Information confidential;


 


(d) Information that is independently developed by or on behalf of the receiving Party, without access to or reliance on the Information received hereunder; or


 


(e) Information that is required to be disclosed by law, including without limitation for litigation, FDA (or foreign equivalent) or SEC requirements or to enforce the terms hereof, provided that the receiving Party gives the disclosing Party prompt notice of such required disclosure and the opportunity to oppose or limit such disclosure.







5.2           Term of Confidentiality. The obligations of confidentiality and non-use set forth herein shall remain in effect for a period of [***] after the last date on which Confidential Information is disclosed by one Party to the other hereunder, or termination of this Agreement, whichever date occurs last.








	
6.

	
INDEMNIFICATION/LIMITATION OF LIABILITY/INSURANCE












6.1           Indemnification








6.1.1 Indemnification by [***].  [***] agrees to defend, indemnify and hold Client, and its officers, directors, employees, members, agents, successors and assigns harmless from claims, demands, costs, expenses (including reasonable attorneys’ fees) and liabilities or losses (hereinafter referred to individually as a “Claim” and collectively as “Claims”) that may be asserted against Client by or on behalf of a third party to the extent that such Claim or Claims result from or arise out of the acts or omissions of [***] or its Affiliates or any bodily injury (including death) based upon (a) any material breach of this Agreement by [***] or (b) the negligence or willfully wrong acts or omissions of [***], its employees, or agents in connection with this Agreement.  Notwithstanding the foregoing, this indemnification and hold harmless provision shall not apply to the extent that any Claim is (A) based upon any negligent or willfully wrong act or omission of Client, its employees, or agents that is the direct cause of the Claim or (B) compromised because Client has failed to give notice of the existence of any Claim or otherwise failed to comply with the provisions of Section 6.1.3 below but only to the extent of the damages resulting therefrom.










6.1.2 Indemnification by Client.  Client agrees to defend, indemnify and hold [***], its Affiliates, and its officers, directors, employees, members, agents, successors and assigns harmless from any and all Claims asserted against [***] by a third party to the extent that such Claim or Claims result from or arise out of the compound, substance, device, or drug (“Product”) that is under investigation by Client, including without limitation (a) any Project protocols and specifications of the Client relating to tests or testing methods to be used by [***] in connection with the Services, (b) the manufacture, distribution, sale or use in any manner of Client’s Product,  (c) any breach of this agreement by Client, or (d) the negligent or willful misconduct of the Client.  Notwithstanding the foregoing, this indemnification and hold harmless provision shall not apply to the extent that any Claim asserted against [***] is (A) based upon any negligent or willfully wrong act or omission of [***], its employees, or agents that is the direct cause of the Claim, or (B) compromised because [***] has failed to give notice of the existence of any Claim or otherwise failed to comply with the provisions of Section 6.1.3 below but only to the extent of the damages resulting therefrom.




 


[***]


 




  





Page 5 of 19











  








 



6.1.3 Notification.  A Party seeking indemnification (the “Indemnified Party”) agrees to promptly notify the other Party (the “Indemnifying Party”), in writing, of any Claim asserted against the Indemnified Party, and shall promptly deliver to the Indemnifying Party a true copy of any such Claim including, but not limited to, a true copy of any summons or other process, pleading or notice issued in any suit or other proceeding to assert or enforce any such Claim.  The Indemnifying Party shall control the investigation, trial and defense of such Claim (including all negotiations to effect settlement) and any appeal arising therefrom, and shall have full authority to settle all economic aspects of the Claim on behalf of the Indemnified Party.  The Indemnified Party shall have the right to approve all non-economic aspects (if any) of the settlement before it becomes final, such approval to be provided promptly and not to be withheld unreasonably, and shall employ or engage attorneys of its own choice.  By way of example, non-economic aspects of a settlement might include admissions of fault or guilt, or agreement to imposition of an obligation or restriction such as an injunction.  The Indemnified Party may, at its own cost, participate in such investigation, trial and defense of such Claim and any appeal arising therefrom.  The Indemnified Party shall provide full cooperation to the Indemnifying Party at all times until the Claim is resolved completely, including (without limitation) providing the Indemnifying Party with all available information concerning the Claim.










6.2           Limitation of Liability.  EXCEPT AS PROVIDED UNDER SECTION 5 (CONFIDENTIALITY) AND SECTION 6 (INDEMNIFICATION), NEITHER PARTY HERETO SHALL BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, PUNITIVE OR SPECIAL DAMAGES OF ANY KIND (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS) ARISING OUT OF OR RELATING TO THIS AGREEMENT.  NOTHING IN THIS SECTION SHALL LIMIT EITHER PARTY'S LIABILITY FOR BODILY INJURY TO A PERSON, DEATH, OR FOR PHYSICAL DAMAGE TO OR DESTRUCTION OF PERSONAL PROPERTY.  EACH PARTY ACKNOWLEDGES THAT THIS WAIVER OF CONSEQUENTIAL AND OTHER DAMAGES REFLECTS THE ALLOCATION OF RISKS BETWEEN THEM AND FORMS AN ESSENTIAL PART OF THE BARGAIN BETWEEN THEM.










6.3           Insurance.  Each Party to this Agreement is responsible for maintaining, at its own expense and throughout the term of this Agreement, programs of insurance or self-insurance as it deems appropriate to protect its liabilities and contractual obligations.  However, failure of either Party to have insurance coverage, inability to obtain insurance coverage, or any inadequacy of insurance coverage of such Party shall not relieve such Party of any part of its liabilities under this Agreement.




 


[***]


 




  





Page 6 of 19











  








 



	
7.

	
DISPUTES/CHOICE OF LAW












7.1           Disputes







7.1.1           Choice of Law/Forum Selection. This Agreement shall be construed and enforced in accordance with the laws of the State of [***] without regard to the conflict of law provisions thereof.  Jurisdiction and venue for litigation of any dispute, controversy or claim arising out of, or in connection with, this Agreement shall be only in a United States federal court or a state court in the state of [***].  Each of the Parties hereby expressly submits to the personal jurisdiction of the foregoing courts located in [***], and waives any objection or defense based on personal jurisdiction or venue that might otherwise be asserted to proceedings in such courts.  Except as specifically provided herein, in any litigation, each Party shall bear its own fees and expenses, including attorneys’ fees.








7.1.2           Waiver of Jury Trial  - Both Parties hereby irrevocably waive, to the fullest extent permitted by law, all right to trial by jury in any action, proceeding or counterclaim (whether in contract, statute, tort (including negligence) or otherwise) relating to or arising from this Agreement.










	
8.

	
REGULATORY COMPLIANCE












8.1             Compliance with Applicable Laws







8.1.1           General.  Each of the Parties represents and warrants to the other Party that it will comply with all laws, rules and regulations applicable to this Agreement ("Applicable Laws"), including, but not limited to, applicable privacy and security regulations and GCP (Good Clinical Practice).  Failure by either Party to comply with any Applicable Laws shall be considered a material breach of this Agreement.




 


8.1.2           Data Retention.




 


a)           [***] will follow all applicable guidelines (including, but not limited to, all applicable Food and Drug Administration (“FDA”) guidelines), laws and regulations with regard to the storage and disposal of clinical trials records








b)           Records.  All Project-specific paper information used by [***] shall be retained for [***] following Project completion.  All such documents in [***] possession after [***] shall be subject to a confidential document destruction process.  If Client requests any of these records to be retrieved by [***] or transfer of these records to Client, retrieval and shipping charges will be the sole responsibility of Client.









c)           Client-Specific Requirements.  Client will advise [***] in writing of any data retention requirements that exceed the standards described in 8.1.2 (a) and 8.1.2(b) above.  [***] will use reasonable efforts to accommodate such requirements for an additional charge.








8.1.3         IATA Dangerous Goods Regulations:









8.1.3.1 Shipment of infectious substances. Client represents and warrants that unless it has specifically informed [***] otherwise on the [***], no shipments sent by Client shall contain risk group 4 pathogens (Category A pathogens as defined in the IATA Dangerous Goods Regulations).  Client acknowledges that under the IATA Dangerous Goods Regulations (i) risk group 4 Category A pathogens should not be transported as Biological substance, category B specimens formerly known as diagnostic specimens and (ii) the shipper, not [***], is responsible for classifying the shipment properly.


 


[***]


 




  





Page 7 of 19











  








 



	
  

	
8.1.3.2  Shipment of other Dangerous Goods.  The shipment of other dangerous goods, such as certain chemicals and dry ice, (“Dangerous Goods”) is subject to local, national, and international laws and regulations.  The person placing the Dangerous Goods in the shipping package is responsible for ensuring that the package, when shipped, meets the requirements of all applicable regulations and any local laws (including any training requirements).  Any information provided by [***] in its [***], Investigator instructions, Investigator meetings, or otherwise, is not intended to be, and should not be considered as, training in the handling of dangerous goods.













	
9.

	
AUDIT







 


During the term of this Agreement and at reasonable times and upon reasonable advance notice, Client may, at Client’s sole cost and expense and in accordance with applicable security policies and procedures of [***], visit [***] facilities to conduct quality assurance audits in connection with the work being performed under this Agreement.  Third-party auditors will be required to sign [***] standard Confidentiality Agreement at the time of their visit to any [***] facility.  Client shall advise [***] in writing, of any special or unusual record keeping needs for the Project and [***] will use reasonable efforts to accommodate Client’s requirements.  Additional charges may apply for any requirements in excess of [***] usual record keeping process.








	
10.

	
ASSIGNMENT OF RIGHTS







 


Except as provided specifically in the Agreement, neither Party may assign this Agreement or any right or interest hereunder without the prior written consent of the other Party.  Any attempted assignment in violation hereof shall be void.  Either Party may assign the Agreement to a successor entity to whom such Party transfers or assigns all or substantially all of its assets or transfers a controlling interest in the Party, or to its parent corporation (if any).  The assigning Party shall provide written notice to the other Party of such assignment.








	
11.

	
MISCELLANEOUS












11.1             Informed Consent.  Unless otherwise specified in this Agreement or an Exhibit, the parties agree that [***] shall not be required to obtain any required patient consents pertaining to its Services performed hereunder, including without limitation testing of DNA or genetic material.  Client and Client’s clinical investigators are responsible for obtaining informed consent for all subjects participating in the Project and for ensuring that the informed consent and Project [***] allow for the performance of all Services to be ordered by Client and its investigators and provided by [***] under this Agreement.  Client shall inform [***] promptly if informed consent is withdrawn to ensure that no further Services are performed on specimens covered by such informed consent.







11.2             Independent Contractor.  [***] is performing the Services as an independent contractor, and not as an employee, agent, partner of, or joint venture with Client.  Neither Party has any authority to bind or act on behalf of the other except as specifically stated herein.












11.3             Entire Agreement.  This Agreement contains the entire understanding between the Parties hereto with respect to the subject matter hereof and supersedes any and all prior agreements, understandings and arrangements between the Parties relating to the subject matter hereof.  No amendment, change, modification or alteration of the terms and conditions hereof shall be binding unless set forth in written form and signed by all the Parties hereto.


 


[***]


 




  





Page 8 of 19











  








 


11.4             Manner of Notice.  All notices permitted under the terms of this Agreement shall be deemed to have been given if delivered personally, or when sent by overnight registered letter or commercial courier to the respective registered addresses of each Party as indicated below:


 



	
If to Client:


ADMA Biologics Inc


65 Commerce Way


Hackensack, NJ 07601


Attention:Adam Grossman

	
With a copy to:


ADMA Biologics 65 Commerce Way


Hackensack, NJ 07601


Attention: General Counsel


	
If to [***]


[***]


[***]


[***]


[***]

	
With a copy to:


[***]


[***]


[***]


[***]












11.5           Publication.  Neither Party shall use the other’s name, trademarks, servicemarks, or other aspects of its corporate identity in any advertising, scientific or professional publications, or promotional literature of any type until prior written approval has been obtained from the other Party.







11.6           No Waiver.  The failure of either Party to exercise or enforce any right conferred upon it hereunder shall not be a waiver of any such right and shall not prevent the exercise or performance thereof at any time or times thereafter; nor shall a waiver of any right hereunder at any given time, including rights to any payments, be deemed a waiver thereof for any other time.







11.7           Force Majeure.  No Party to this Agreement shall be liable for failure to perform any duty or obligation that such Party may have under this Agreement where such failure has been occasioned by any act of God, fire, strike, inevitable accident, war or any cause outside the reasonable control of the Party who had the duty to perform; provided, however, that the non-performing Party shall give prompt notice to the other Party of the reason for its non-performance and its reasonable best estimate of when performance would begin again.  The non-performing Party shall promptly begin to perform again after the intervening event has concluded.







11.8           Severability.  If any provision of this Agreement is held to be illegal, invalid, or unenforceable by a court of competent jurisdiction, the Parties shall, if possible, agree on a legal, valid and enforceable substitute provision which is as similar in effect to the deleted provision as possible.  The remaining portion of this Agreement not declared illegal, invalid or unenforceable shall, in any event, remain valid and effective for the term remaining unless the provision found illegal, invalid or unenforceable goes to the essence of this Agreement.








11.9           Debarment.  [***] certifies that no person employed or engaged by [***] to perform any Services has been debarred under Section 306 of the United States Federal Food, Drug, and Cosmetic Act.  To the extent that [***] becomes debarred or receives notice that any debarment proceedings have been initiated, [***] shall provide Client with written notice thereof.




  


[***]


 




  





Page 9 of 19











  






 


11.10   Export Control.  It is understood and agreed by the parties that [***] shall not provide Services or support to any entity or individual located in any of the countries identified in the then-current (a) list of countries subject to embargo as identified by the Department of Commerce’s Bureau of Industry and Security pursuant to the federal Export Administration Regulations and/or (b) list of sanction programs of the Treasury Department’s Office of Foreign Assets Control pursuant to 31 CFR Parts 500 et seq. (the “Prohibited Countries”).  Furthermore, Client represents, covenants and warrants that neither Client nor its participating investigators shall submit specimens or samples pursuant to this Agreement for Services or support by [***] that originate from any of the Prohibited Countries.  In the event that [***] detects or becomes aware that Client or Client's investigators submitted a specimen/sample from any of the Prohibited Countries to [***] or if it is discovered that Client or any of Client's investigators are located in one of the Prohibited Countries, [***] shall have the right to immediately terminate this Agreement.


 


[***]


 




  





Page 10 of 19











  








 


IN WITNESS WHEREOF, Client and [***] have duly executed this Agreement on the first day above written.


 


 



	ADMA BIOLOGICS, INC.  	
[***]


[***]


	 	 
	_______________________________________	_______________________________________ 
	Signature 	Signature
	 	 
	Name printed ____________________________  	[***]
	 	 
	Title: __________________________________	[***]
	 	 
	Date: __________________________________	Date: ___________________________________





 


[***]


 




  





Page 11 of 19











  






 


 


EXHIBIT A


[***]


 


The [***] is not attached to this Service Agreement.  [***] will prepare and obtain Client’s approval of this document.  Upon Client’s signature of the [***], it will become a part of this Service Agreement.


 


[***]

 




  





Page 12 of 19











  








 


EXHIBIT B


BUDGET Version [***], Dated [***]


CONFIDENTIAL




 


[***]


[***]


 



ADMA Biologics, Inc.


[***]


[***]


28-Mar-12


 









 





	Prepared for:   	
Adam Grossman (ADMA)

	
by: [***]


	 	  	
       [***]


	 	
ADMA Biologics, Inc.

	
       [***]


	 	
65 Commerce Way

	
       [***]


	 	
Hackensack, NJ 07601

	
       [***]


	 	  	  
	 	  	  
	    Tel: 201-478-5552 [***]	
       [***]


	 	  	
       [***]


	      Email: [***]	
Email: [***]












[***]


 




  





Page 13 of 19











  






 


[***]


 


28-Mar-12


 


Adam Grossman (ADMA)


ADMA Biologics, Inc.


65 Commerce Way


Hackensack, NJ 07601








	
Regarding:

	
[***]








	
  

	
[***]







 


Dear Adam :


 


Thank you for the opportunity to submit a revised proposal for your study.


 


[***] has a commitment to peak performance, superior value for our customers, teamwork, innovation and integrity.  We look forward to the opportunity to work with you to demonstrate our dedication to these values.


 


The prices given in this quotation are valid for a period of three months.


 


If you have any questions or require further assistance, please feel free to call me.


 


Yours sincerely,


 


 


[***]


[***]


[***]


 


 


[***]


 




  





Page 14 of 19











  






 




	
ADMA Biologics, Inc.

	 	
[***]


	 	
Quote for Services

	 





 




[***]


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


[***]


 


 


[***]


 




  





Page 15 of 19











  






 



	
ADMA Biologics, Inc.

	 	
[***]


	 	
Quote for Services

	 





 


Proposal Summary


[***]


 






   



	
Quote Date: 


Quote Expiration Date: 

	
[***]


[***]







 









 




Estimated Grand Total Amount          [***]


 


Proposal Summary 1


 



	

Sub Totals



	 	

Region



	 	

Billing Amount



	 	

Conversion Rate



	 	

Estimated Total Amount




	  	 	  	 	  	 	  	 	  
	  	 	
[***]

	 	
[***]

	 	
[***]

	 	

[***]




	  	 	  	 	  	 	  	 	

[***]














Detailed Proposal Summary


 



	

Testing



	 	

Region



	 	

Billing Amount



	 	

Conversion Rate



	 	

Estimated Total Amount




	  	 	  	 	  	 	  	 	  
	  	 	
[***]

	 	
[***]

	 	
[***]

	 	

[***]




	
[***]

	 	  	 	  	 	  	 	

[***]















	

Study Management



	 	

Region



	 	

Billing Amount



	 	

Conversion Rate



	 	

Estimated Total Amount




	  	 	  	 	  	 	  	 	  
	  	 	
[***]

	 	
[***]

	 	
[***]

	 	

[***]




	
[***]

	 	  	 	  	 	  	 	

[***]









 


[***]


 




  





Page 16 of 19











  






 



	
ADMA Biologics, Inc.

	 	
[***]


	 	
Quote for Services

	 





 


Detail Summary


[***]


 



	

Testing



	 	

Region



	 	

Time Points



	 	

Quantity



	 	

Billing Currency Unit Price



	 	

Billing Amount



	 	

Conversion Rate



	 	

Estimated Total Amount




	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]


	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]


	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	

[***]




	
[***]

	 	  	 	  	 	  	 	  	 	  	 	  	 	

[***]















	

 
Testing





	 	

Region



	 	

Unit



	 	

Quantity



	 	

Billing Currency Unit Price



	 	

Billing Amount



	 	

Conversion Rate



	 	

Estimated Total Amount




	
[***]

	 	
[***]

	 	  	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]


	
[***]

	 	
[***]

	 	  	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	

[***]




	
[***]

	 	  	 	  	 	  	 	  	 	  	 	  	 	

[***]









 


[***]


 




  





Page 17 of 19











  









	
ADMA Biologics, Inc.

	 	
[***]


	 	
Quote for Services

	 





 




Test Visit Schedule


All Locations


[***]


 



	

Category



	 	

Name



	 	

[***]



	 	

[***]



	 	

[***]



	 	

[***]



	 	

[***]



	 	

[***]



	 	

[***]



	 	

[***]



	 	

[***]



	 	

Month 10 4 batches



	 	

Month 11 4 batches



	 	

Month 12 4 batches




	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
1250

	 	
1000

	 	
1250


	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
375

	 	
300

	 	
375


	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
[***]

	 	
0

	 	
0

	 	
0







 


[***]


 




  





Page 18 of 19











  






 




	
ADMA Biologics, Inc.

	 	
[***]


	 	
Quote for Services

	 





 




End Notes


[***]


 


Global Summary


 



	
  

	
1

	
See Study Specific Assumptions and Pricing Model, herein.  Budget excludes any “TBD” (To Be Determined) items.







 


Global Summary - [***]


 



	 	
1BT

	
Quoted fees reflect [***].







 



	 	
2BT

	
The sample testing fees include the [***] into a [***] laboratory, [***] of the [***], [***], [***] and [***].







 



	 	
3BT

	
The [***] testing fees also include [***] and [***] as applicable and agreed in the [***].  Any final result reports issued in hard copy will be sent via standard postal service or (within the continental United States only) [***] proprietary courier.







 


Global Summary - [***]


 



	 	
1SM

	
The [***] includes:







 


— [***]


— [***]


— [***]


— [***]


— [***]


— [***]


— [***]


— [***]


 



	 	
2SM

	
The [***] fee includes:







 


— [***]


 


[***]




Page 19 of 19